STOCK TITAN

Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

RCM Eos PIPE HOLDINGS, LLC filed a Schedule 13D disclosing a significant investment in Pulmatrix, Inc. It purchased 1,000 shares of Series B Convertible Preferred Stock for $1,000,000, which are convertible into 405,358 Pulmatrix common shares, equal to 9.99% of the company’s common stock on an as-converted basis.

The preferred shares convert at roughly 454.55 common shares per preferred share at a $2.20 conversion price and carry 8% cumulative dividends payable in stock. This financing is tied to a planned merger in which Eos SENOLYTIX stockholders and related investors are expected to own about 94% of the combined company, leaving existing Pulmatrix stockholders with about 6% on a fully diluted basis.

Positive

  • None.

Negative

  • Substantial dilution and control shift: After the planned merger, pre-merger Eos stockholders and related investors are expected to own about 94% of the combined company, leaving existing Pulmatrix stockholders with roughly 6% on a fully diluted basis.

Insights

Eos-related investor funds Pulmatrix ahead of a merger that will heavily dilute existing holders.

RCM Eos PIPE HOLDINGS, LLC invested $1,000,000 in Pulmatrix via 1,000 shares of Series B Convertible Preferred Stock. These securities convert at a $2.20 price into 405,358 common shares, capped by a 9.99% beneficial ownership blocker.

The investment is structured as interim financing ahead of a merger where Eos SENOLYTIX will combine with Pulmatrix. Based on the disclosed exchange ratio, pre-merger Eos stockholders and related investors are expected to own about 94% of the combined company, while current Pulmatrix stockholders would hold roughly 6% on a fully diluted basis.

This implies substantial dilution and a transfer of control toward Eos-affiliated holders. Up to $250,000 of the proceeds may be used for working capital before the merger closes, with the remainder restricted. A Voting Agreement commits the preferred and related common shares to support approval of the merger and related transactions.

Investment amount $1,000,000 Aggregate funds used to purchase Series B Convertible Preferred Stock
Preferred shares purchased 1,000 shares Series B Convertible Preferred Stock acquired by RCM Eos
Conversion ratio 454.55 shares per preferred share Approximate common shares received for each preferred share
As-converted common shares 405,358 shares Common stock into which the preferred is convertible, subject to blocker
Ownership percentage 9.99% Portion of Pulmatrix common stock represented on an as-converted basis
Shares outstanding 3,652,285 shares Pulmatrix common shares outstanding as of February 23, 2026
Dividend rate 8% per annum Cumulative dividends on Series B Preferred, payable in common stock
Pro forma ownership split 94% Eos / 6% Pulmatrix holders Expected fully diluted ownership after the merger
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
Series B Convertible Preferred Stock financial
"owns all of the issued and outstanding shares of Series B Convertible Preferred Stock of Pulmatrix, Inc."
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
beneficial ownership blocker financial
"subject to a 9.99% beneficial ownership blocker"
Certificate of Designation regulatory
"the Issuer filed the Certificate of Designation with the Secretary of State of the State of Delaware"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
Voting Agreement regulatory
"RCM Eos entered into a Voting Agreement, dated March 26, 2026"
Agreement and Plan of Merger and Reorganization regulatory
"that certain Agreement and Plan of Merger and Reorganization, dated March 26, 2026"





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
RCM Eos PIPE HOLDINGS, LLC, a Delaware limited liability company owns all of the issued and outstanding shares of Series B Convertible Preferred Stock of Pulmatrix, Inc. (the "Issuer"). The Series B Convertible Preferred Stock is convertible into shares of Common Stock, par value $0.0001 per share, of the Issuer, at a ratio of approximately 454.55 shares of Common Stock for each share of Preferred Stock, subject to a 9.99% beneficial ownership blocker. RCM Eos PIPE HOLDINGS, LLC is controlled by its manager, Rapha Capital Management, LLC, a Delaware limited liability company, which is in turn managed by its manager, Kevin M. Slawin. The above listed shares are based on 3,652,285 shares of Common Stock of the Issuer outstanding on February 23, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, and the actual number of shares may differ at the time of the conversion, subject to the 9.99% beneficial ownership blocker.


SCHEDULE 13D




Comment for Type of Reporting Person:
RCM Eos PIPE HOLDINGS, LLC, a Delaware limited liability company owns all of the issued and outstanding shares of Series B Convertible Preferred Stock of the Issuer. The Series B Convertible Preferred Stock is convertible into shares of Common Stock, par value $0.0001 per share, of the Issuer, at a ratio of approximately 454.55 shares of Common Stock for each share of Preferred Stock, subject to a 9.99% beneficial ownership blocker. RCM Eos PIPE HOLDINGS, LLC is controlled by its manager, Rapha Capital Management, LLC, a Delaware limited liability company, which is in turn managed by its manager, Kevin M. Slawin. The above listed shares are based on 3,652,285 shares of Common Stock of the Issuer outstanding on February 23, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, and the actual number of shares may differ at the time of the conversion, subject to the 9.99% beneficial ownership blocker.


SCHEDULE 13D




Comment for Type of Reporting Person:
RCM Eos PIPE HOLDINGS, LLC, a Delaware limited liability company owns all of the issued and outstanding shares of Series B Convertible Preferred Stock of the Issuer. The Series B Convertible Preferred Stock is convertible into shares of Common Stock, par value $0.0001 per share, of the Issuer, at a ratio of approximately 454.55 shares of Common Stock for each share of Preferred Stock, subject to a 9.99% beneficial ownership blocker. RCM Eos PIPE HOLDINGS, LLC is controlled by its manager, Rapha Capital Management, LLC, a Delaware limited liability company, which is in turn managed by its manager, Kevin M. Slawin. The above listed shares are based on 3,652,285 shares of Common Stock of the Issuer outstanding on February 23, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, and the actual number of shares may differ at the time of the conversion, subject to the 9.99% beneficial ownership blocker.


SCHEDULE 13D


RCM Eos PIPE HOLDINGS, LLC
Signature:By: Rapha Capital Management, LLC, its Manager, By: /s/ Kevin M. Slawin
Name/Title:Kevin M. Slawin/President
Date:04/22/2026
Slawin Kevin M.
Signature:/s/ Kevin M. Slawin
Name/Title:Kevin M. Slawin
Date:04/22/2026
Rapha Capital Management, LLC
Signature:/s/ Kevin M. Slawin
Name/Title:Kevin M. Slawin/President
Date:04/22/2026

FAQ

What stake in Pulmatrix (PULM) does RCM Eos report on this Schedule 13D?

RCM Eos PIPE HOLDINGS, LLC reports beneficial ownership of 405,358 Pulmatrix common shares on an as-converted basis. This represents 9.99% of the company’s common stock, based on 3,652,285 shares outstanding as of February 23, 2026, per Pulmatrix’s latest annual report.

How much did RCM Eos invest in Pulmatrix (PULM) and what did it buy?

RCM Eos invested approximately $1,000,000 in Pulmatrix to buy 1,000 shares of Series B Convertible Preferred Stock. These preferred shares were purchased in a private placement under a Securities Purchase Agreement dated March 26, 2026, and closed on April 16, 2026.

What are the key conversion terms of Pulmatrix (PULM) Series B Convertible Preferred Stock?

Each Pulmatrix Series B Convertible Preferred share converts into about 454.55 common shares at a $2.20 per-share conversion price, subject to adjustments. A 9.99% beneficial ownership blocker limits how much can be converted at once relative to outstanding common shares.

How will the Pulmatrix (PULM) and Eos SENOLYTIX merger affect ownership?

Based on the merger’s exchange ratio, pre-merger Eos stockholders and related investors are expected to own about 94% of the combined company. Existing Pulmatrix stockholders would hold roughly 6% on a fully diluted basis, excluding equity incentive plan reserves.

What dividends and voting rights come with Pulmatrix (PULM) Series B Preferred?

The Series B Convertible Preferred Stock carries 8% cumulative annual dividends, payable in common shares upon conversion dates. Holders vote together with common stockholders as a single class on an as-converted basis, subject to a beneficial ownership limitation in the Certificate of Designation.

How can Pulmatrix (PULM) use the $1,000,000 proceeds from the preferred stock sale?

Under the Securities Purchase Agreement, Pulmatrix may use up to $250,000 of the net proceeds for working capital and general corporate purposes. Use of the remaining proceeds is subject to specific restrictions set out in the agreement prior to closing of the merger.